Ocrevus, rituximab may not slow disability progression in PPMS

Discuss Ocrelizumab, a monoclonal antibody treatment for MS.
Post Reply
User avatar
DIM
Family Elder
Posts: 633
Joined: Thu Feb 28, 2008 3:00 pm
Location: GREECE
Contact:
Contact DIM

Ocrevus, rituximab may not slow disability progression in PPMS

Post by DIM »

Anti-CD20 therapies like Ocrevus (ocrelizumab) and rituximab appear to be ineffective at slowing disability progression in people with primary progressive multiple sclerosis (PPMS), a form of the disease characterized by symptoms that steadily worsen over time, according to data from a real-world study in France.

https://multiplesclerosisnewstoday.com/ ... sion-ppms/
Top
Post Reply

Return to “Ocrevus (Ocrelizumab)”